HRP20200554T1 - Spojevi derivata heterocikličkih alkila koji služe kao selektivni inhibitori histonske deacetilaze i farmaceutski pripravci koji ih sadrže - Google Patents

Spojevi derivata heterocikličkih alkila koji služe kao selektivni inhibitori histonske deacetilaze i farmaceutski pripravci koji ih sadrže Download PDF

Info

Publication number
HRP20200554T1
HRP20200554T1 HRP20200554TT HRP20200554T HRP20200554T1 HR P20200554 T1 HRP20200554 T1 HR P20200554T1 HR P20200554T T HRP20200554T T HR P20200554TT HR P20200554 T HRP20200554 T HR P20200554T HR P20200554 T1 HRP20200554 T1 HR P20200554T1
Authority
HR
Croatia
Prior art keywords
alkyl
independently
halogen
formula
image
Prior art date
Application number
HRP20200554TT
Other languages
English (en)
Inventor
Changsik LEE
Jaekwang Lee
Hyeseung SONG
Daekwon BAE
Nina Ha
Il Hyang Kim
Original Assignee
Chong Kun Dang Pharmaceutical Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Pharmaceutical Corp. filed Critical Chong Kun Dang Pharmaceutical Corp.
Publication of HRP20200554T1 publication Critical patent/HRP20200554T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Claims (8)

1. Spoj, naznačen time, da je predstavljen sljedećom formulom I, njegov optički izomer ili njegova farmaceutski prihvatljiva sol: [Formula I] [image] pri čemu X je heterocikloalkil odabran iz skupine koja se sastoji od sljedećih: [image] [image] {gdje je svaki od Z i W neovisno C ili N, a barem jedan od Z i W je N, svaki od a, b, c i d je neovisno 1, 2 ili 3, i svaki od R3, R4, R5 i R6 je neovisno -H ili -C1-C4-alkil}; Y je C ili N; svaki od A i B je neovisno –C1-C4-alkil, -C6-C10-aril, -C3-C12-heteroaril, -C3-C10-cikloalkil, -C2-C10-heterocikloalkil ili -C3-C10-cikloalkenil {gdje jedan ili više atoma vodika od -C1-C4-alkila, mogu biti supstituirani s -OH ili halogenom, i svaki od –C6-C10-arila, -C3-C12-heteroarila, -C3-C10-cikloalkila, -C2-C10-heterocikloalkila ili -C3-C10-cikloalkenila, može biti neovisno nesupstituiran ili supstituiran sa sljedećima: -OH, -C1-C4-alkil, -OC1-C4-alkil, -CF3 ili halogen najednom ili više njihovih atoma vodika}; Q je C=O ili SO2; R1 je -H ili -C1-C4-alkil; R2 je -H, -OH, -C1-C4-alkil, -C1-C4-alkilhidroksi, halogen ili nula {uz uvjet da kada Y je C, tada R2 je -H, -OH, -C1-C4-alkil ili –C1-C4-alkilhidroksi, i kada Y je N, tada R2 je nula}; i n je 1, 2, 3 ili 4.
2. Spoj koji je predstavljen formulom I, njegov optički izomer ili njegova farmaceutski prihvatljiva sol, prema patentnom zahtjevu 1, naznačen time, da X je [image] {gdje je svaki od Z i W neovisno C ili N, a barem jedan od Z i W je N, svaki od a, b, c i d je neovisno 1, 2 ili 3, i svaki od R3, R4, R5 i R6 je neovisno -H ili -C1-C4-alkil}; Y je C ili N; svaki od A i B je neovisno -C1-C4-alkil, -C6-C10-aril, -C3-C12-heteroaril, {gdje jedan ili više atoma vodika od -C1-C4-alkila, mogu biti supstituirani s -OH ili halogenom, i svaki od -C6-C10-arila ili -C3-C12-heteroarila, može biti neovisno nesupstituiran ili supstituiran sa sljedećima: -OH, -C1-C4-alkil, -OC1-C4-alkil, -CF3 ili halogen na jednom ili više njihovih atoma vodika}; Q je C=O ili SO2; R1 je -H ili -C1-C4-alkil; R2 je -H, -OH, halogen ili nula {uz uvjet da kada Y je C, tada R2 je -H, -OH ili halogen, i kada Y je N, R2 je tada nula}; i n je 1, 2, 3 ili 4.
3. Spoj koji je predstavljen formulom I, njegov optički izomer ili njegova farmaceutski prihvatljiva sol, prema patentnom zahtjevu 2, naznačen time, da X je [image] {gdje je svaki od Z i W neovisno C ili N, a barem jedan od Z i W je N, i svaki od R3 i R4 je neovisno -H ili -C1-C4-alkil}; Y je C ili N; svaki od A i B je neovisno -C1-C4-alkil, -C6-C10-aril ili -C3-C12-heteroaril, {gdje jedan ili više atoma vodika od -C1-C4-alkila, mogu biti supstituirani s -OH ili halogenom, i svaki od -C6-C10-arila i -C3-C12-heteroarila, može biti neovisno nesupstituiran ili supstituiran sa sljedećima: -OH, -C1-C4-alkil, -OC1-C4-alkil, -CF3 ili halogen najednom ili više njihovih atoma vodika}; Q je C=O; R1 je -H ili -C1-C4-alkil; R2 je -H, -OH, halogen ili nula {uz uvjet da kada Y je C, tada R2 je -H, -OH ili halogen, i kada Y je N, tada R2 je nula}; i n je 3.
4. Spoj koji je predstavljen formulom I, njegov optički izomer ili njegova farmaceutski prihvatljiva sol, prema patentnom zahtjevu 1, naznačen time, da je spoj koji je predstavljen formulom I, odabran iz skupine koja se sastoji od spojeva opisanih u sljedećoj tablici: [image] nastavak [image] nastavak [image]
5. Spoj koji je predstavljen formulom I, njegov optički izomer ili njegova farmaceutski prihvatljiva sol, prema patentnom zahtjevu 4, naznačen time, da je spoj koji je predstavljen formulom I, odabran iz skupine koja se sastoji od spojeva opisanih u sljedećoj tablici: [image]
6. Farmaceutski pripravak, naznačen time, da se upotrebljava u prevenciji ili liječenju bolesti posredovane histonskom deacetilazom, dok on kao djelatni sastojak, obuhvaća spoj koji je predstavljen formulom I, njegov optički izomer ili njegovu farmaceutski prihvatljivu sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 5.
7. Farmaceutski pripravak prema patentnom zahtjevu 6, naznačen time, da se kod bolesti posredovane histonskom deacetilazom, radi o bolesti stanične proliferacije, upalnoj bolesti, dominantnoj autosomalnoj bolesti, genetskoj metaboličkoj bolesti, autoimunoj bolesti, akutnoj/kroničnoj neurološkoj bolesti, hipertrofiji, srčanom zastoju, očnoj bolesti ili neurodegenerativnoj bolesti.
8. Spoj koji je predstavljen formulom I, njegov optički izomer ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da se upotrebljava u postupku liječenja bolesti posredovane histonskom deacetilazom.
HRP20200554TT 2015-05-22 2020-04-04 Spojevi derivata heterocikličkih alkila koji služe kao selektivni inhibitori histonske deacetilaze i farmaceutski pripravci koji ih sadrže HRP20200554T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150071665 2015-05-22
PCT/KR2016/005411 WO2016190630A1 (en) 2015-05-22 2016-05-20 Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same
EP16800269.9A EP3297992B1 (en) 2015-05-22 2016-05-20 Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same

Publications (1)

Publication Number Publication Date
HRP20200554T1 true HRP20200554T1 (hr) 2020-07-24

Family

ID=57393368

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200554TT HRP20200554T1 (hr) 2015-05-22 2020-04-04 Spojevi derivata heterocikličkih alkila koji služe kao selektivni inhibitori histonske deacetilaze i farmaceutski pripravci koji ih sadrže

Country Status (22)

Country Link
US (1) US11420950B2 (hr)
EP (1) EP3297992B1 (hr)
JP (1) JP6507267B2 (hr)
KR (1) KR101796601B1 (hr)
CN (1) CN108026057B (hr)
AU (1) AU2016267872B2 (hr)
BR (1) BR112017024952A2 (hr)
CA (1) CA2985769C (hr)
DK (1) DK3297992T3 (hr)
ES (1) ES2776680T3 (hr)
HK (1) HK1251556A1 (hr)
HR (1) HRP20200554T1 (hr)
HU (1) HUE049645T2 (hr)
MX (1) MX2017014953A (hr)
MY (1) MY195058A (hr)
NZ (1) NZ736015A (hr)
PH (1) PH12017501823B1 (hr)
PL (1) PL3297992T3 (hr)
PT (1) PT3297992T (hr)
RU (1) RU2683022C1 (hr)
TW (1) TWI617545B (hr)
WO (1) WO2016190630A1 (hr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6827113B2 (ja) 2017-01-21 2021-02-10 広州白雲山漢方現代薬業有限公司Ｇｕａｎｇｚｈｏｕ Ｈａｎｆａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ． シェーグレン症候群の治療におけるペオニフロリン−６’−ｏ−ベンゼンスルホン酸の使用
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
KR20190118251A (ko) * 2018-04-10 2019-10-18 주식회사 종근당 건성안의 예방 또는 치료를 위한 조성물
RU2722694C1 (ru) * 2019-12-17 2020-06-03 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ УНИТАРНОЕ ПРЕДПРИЯТИЕ "ИНСТИТУТ ХИМИЧЕСКИХ РЕАКТИВОВ И ОСОБО ЧИСТЫХ ХИМИЧЕСКИХ ВЕЩЕСТВ НАЦИОНАЛЬНОГО ИССЛЕДОВАТЕЛЬСКОГО ЦЕНТРА "КУРЧАТОВСКИЙ ИНСТИТУТ" (НИЦ "Курчатовский институт - ИРЕА) Способ получения N-((гидроксиамино)-оксоалкил)-2-(хиназолин-4-иламино)-бензамидов
CN114957132A (zh) * 2021-02-20 2022-08-30 中国科学院上海药物研究所 含s构型的氨基苯甲酰胺基哒嗪酮类化合物、其制备方法、药物组合物及应用
CN113582911B (zh) * 2021-08-12 2024-03-12 山东大学 多靶点多奈哌齐-异羟肟酸型化合物及其制备方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US385069A (en) 1888-06-26 Device for sprinkling lawns
USRE38506E1 (en) 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
PL334846A1 (en) 1997-01-23 2000-03-27 Hoffmann La Roche Sulphamidic inhibitors of metaloproteases
AU2268401A (en) * 1999-12-17 2001-06-25 Versicor Inc Novel succinate compounds, compositions and methods of use and preparation
US6852752B2 (en) * 1999-12-17 2005-02-08 Vicuron Pharmaceuticals Inc. Urea compounds, compositions and methods of use and preparation
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2002030879A2 (en) 2000-09-29 2002-04-18 Prolifix Limited Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
DE60138658D1 (de) 2000-09-29 2009-06-18 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine Amidgruppe zur Behandlung von Malaria
DE10111892C1 (de) * 2001-03-13 2002-08-22 Gkn Sinter Metals Gmbh Gesinterter, hochporöser Körper
WO2002074298A1 (fr) 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Inhibiteurs de production d'il-6
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
ES2306858T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de carbonilamino como nuevos inhibidores de las histonadesacetilasas.
JP4606027B2 (ja) 2002-04-03 2011-01-05 トポターゲット ユーケー リミテッド Ｈｄａｃ阻害剤としてのピペラジン結合を有するカルバミン酸化合物
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2007512367A (ja) * 2003-11-26 2007-05-17 エートン ファーマ インコーポレーティッド ジアミンおよびイミノ二酢酸ヒドロキサム酸誘導体
WO2007017728A2 (en) 2005-08-05 2007-02-15 Orchid Research Laboratories Limited Novel heterocyclic compounds
KR20080052611A (ko) 2005-08-26 2008-06-11 메틸진 인크. 히스톤 탈아세틸 효소의 벤조디아제핀 및 벤조피페라진유도체 억제제
US20070207950A1 (en) 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
WO2007074176A1 (es) * 2005-12-27 2007-07-05 Universidad Del Pais Vasco - Euskal Herriko Unibertsitatea (Upv-Ehu) Nuevos derivados pirrólicos con actividad inhibidora de desacetilasas de histonas
ES2689444T3 (es) 2006-11-22 2018-11-14 Incyte Holdings Corporation Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
HUE025349T2 (en) 2009-01-23 2016-02-29 Euro Celtique Sa Hydroxamic acid derivatives
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
KR101168801B1 (ko) * 2009-03-27 2012-07-25 주식회사종근당 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물
KR101481872B1 (ko) 2009-09-10 2015-01-12 에프. 호프만-라 로슈 아게 Ｊａｋ의 억제제
EP2526093B1 (en) 2010-01-22 2016-08-17 Acetylon Pharmaceuticals, Inc. Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
US8472724B2 (en) * 2010-06-30 2013-06-25 Samsung Electronics Co., Ltd. System and method for reducing noise in an image
WO2012012322A1 (en) 2010-07-19 2012-01-26 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012012320A1 (en) 2010-07-19 2012-01-26 Millenium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
CN102775368B (zh) * 2011-05-10 2016-08-17 上海驺虞医药科技有限公司 一类噻唑类化合物及其制备方法和用途
US9512083B2 (en) 2011-07-20 2016-12-06 The General Hospital Corporation Histone deacetylase 6 selective inhibitors for the treatment of bone disease
JP2015515279A (ja) 2012-04-19 2015-05-28 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 治療に反応する患者を同定するバイオマーカーおよびそのような患者の治療
RU2634694C2 (ru) * 2013-04-29 2017-11-03 Чонг Кун Данг Фармасьютикал Корп. Новые соединения для селективных ингибиторов гистондеацетилазы и фармацевтическая композиция, включающая такие соединения
CN103301953B (zh) 2013-06-19 2015-05-20 中南大学 6-芳基酰胺基己基羟肟酸捕收剂及其制备和应用方法
KR101697518B1 (ko) 2014-03-12 2017-01-19 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
WO2016190630A1 (en) 2016-12-01
KR20160137441A (ko) 2016-11-30
BR112017024952A2 (pt) 2018-07-31
PT3297992T (pt) 2020-03-17
JP6507267B2 (ja) 2019-04-24
CA2985769C (en) 2019-08-20
KR101796601B1 (ko) 2017-11-10
ES2776680T3 (es) 2020-07-31
EP3297992B1 (en) 2020-02-05
TWI617545B (zh) 2018-03-11
CA2985769A1 (en) 2016-12-01
PH12017501823A1 (en) 2018-04-23
NZ736015A (en) 2019-04-26
US20180312482A1 (en) 2018-11-01
AU2016267872A1 (en) 2017-10-26
DK3297992T3 (da) 2020-04-20
PH12017501823B1 (en) 2018-04-23
MX2017014953A (es) 2018-08-15
CN108026057B (zh) 2021-08-06
US11420950B2 (en) 2022-08-23
AU2016267872B2 (en) 2019-01-17
RU2683022C1 (ru) 2019-03-26
HK1251556A1 (zh) 2019-02-01
EP3297992A1 (en) 2018-03-28
MY195058A (en) 2023-01-05
TW201706246A (zh) 2017-02-16
CN108026057A (zh) 2018-05-11
PL3297992T3 (pl) 2020-07-27
JP2018517693A (ja) 2018-07-05
EP3297992A4 (en) 2018-12-26
HUE049645T2 (hu) 2020-09-28

Similar Documents

Publication Publication Date Title
HRP20200554T1 (hr) Spojevi derivata heterocikličkih alkila koji služe kao selektivni inhibitori histonske deacetilaze i farmaceutski pripravci koji ih sadrže
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
DK3606909T3 (da) Natriumsalt af n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1h-pyrazol-3-sulfonamid
HRP20130976T1 (hr) Karbonilaminopirolopirazoli, potentni inhibitori kinaza
HRP20230342T1 (hr) Kationski lipid koji se može ionizirati za isporuku rna
WO2017132432A8 (en) Benzimidazole derivatives as modulators of ror-gamma
EA201691136A1 (ru) Производное на основе 1,2-нафтохинона и способ его получения
NZ597109A (en) Tablet composition having favorable dissolution property useful as an anticoagulant
AR080982A1 (es) Derivados de quinoxalina
HRP20211429T1 (hr) Derivati sobetiroma
EA201791903A1 (ru) β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ
HRP20211278T1 (hr) Supstituirani derivati indolina kao inhibitori replikacije denga virusa
HRP20150427T1 (hr) Ne-nukleozidni inhibitori reverzne transkriptaze
EA201000104A1 (ru) Производные пиримидина, применимые для лечения воспалительных или аллергических патологических состояний
PE20220386A1 (es) Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b
AR109952A1 (es) Derivados de fenilamina 4-sustituidos y su uso para proteger cultivos al combatir microorganismos fitopatogénicos indeseados
HRP20211907T1 (hr) Pirazol – oksazolidinon spoj za anti – hepatitis b virus
HRP20201932T4 (hr) Stimulatori / aktivatori topive gvanilat-ciklaze u kombinaciji s nep-inhibitorom i/ili angiotenzin aii-antagonistom i njihova uporaba
GEP20207128B (en) Aminothiazole derivatives useful as antiviral agents
RS54595B1 (en) 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives
HRP20181027T1 (hr) Derivati fuzioniranog triazola kao inhibitori fosfodiesteraze 10a
RU2019139886A (ru) Терапевтическое средство против дисфункции мейбомиевых желез
RU2017124423A (ru) Соединения дигидропиримидин-2-она и их медицинское применение
EP3620457A4 (en) COMPOUND DERIVED FROM PYRIMIDINE, OPTICAL ISOMER, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING A TYRO 3-RELATED DISEASE, CONSIDERING IT AS AN ACTIVE INGREDIENT
WO2013101911A3 (en) Benzimidazole derivatives as selective blockers of persistent sodium current